Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS)

Evoy, Kirk E.; Covvey, Jordan R.; Peckham, Alyssa M.; Ochs, Leslie; Hultgren, Kyle E.

doi:10.1016/j.sapharm.2018.06.018

Cited by 80 publications

(66 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its quality (euphoric or sedative effect) will be mainly dependent on the person, but mostly on the dosage and the method of application used. Looking at the identified reported cases, male sex and history of substance abuse are major common characteristics for PRG abuse/misuse; this is in line with the existing literature [21,22,23,24,25,26,27]. Chiappini et al performed a descriptive analysis of data retrieved from EudraVigilance database and observed that in 6.6% of all cases reporting PRG related adverse reactions (AR), the AR was due to abuse/misuse of the substance [28].…”

Section: Discussionsupporting

confidence: 83%

Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions

et al. 2019

View full text Add to dashboard Cite

Background: It is repeatedly reported that pregabalin (PRG) and gabapentin feature a potential for abuse/misuse, predominantly in patients with former or active substance use disorder. The most common route of use is oral, though reports of sublingual, intravenous, rectal, and smoking administration also exist. A narrative review was performed to provide an overview of current knowledge about nasal PRG use. Methods: A narrative review of the currently available literature of nasal PRG use was performed by searching the MEDLINE, EMBASE, and Web of Science databases. The abstracts and articles identified were reviewed and examined for relevance. Secondly, a request regarding reports of cases of nasal PRG administration was performed in the worldwide spontaneous reporting system of adverse drug reactions of the European Medicines Agency (EMA, EudraVigilance database). Results: The literature search resulted in two reported cases of nasal PRG use. In the analysis of the EMA-database, 13 reported cases of nasal PRG use (11 male (two not specified), mean age of users = 34.2 years (four not specified)) were found. In two cases fatalities occurred related to PRG nasal use. Conclusions: Even if only little evidence can be found in current literature, the potential for misuse/abuse of PRG via nasal route might be of particular importance in the near future in PRG users who misuse it. Physicians should be aware of these alternative routes of administration.

show abstract

Section: Discussionsupporting

confidence: 83%

Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In the USA, the FDA Adverse Events Reporting System (FAERS) showed only 576 cases of gabapentin abuse and 58 cases of pregabalin abuse among reported adverse events over the 5-year period spanning 2012-2016 [43], with the caveat that by the FDA's admission these reports are unvalidated, possibly duplicated, and are without any mechanism for evaluating association let alone causality. To put these numbers into perspective, over 195 million gabapentin prescriptions and 47 million pregabalin prescriptions were written in the USA during that time period [44].…”

Section: Mechanism: Limited (And Conflicting) Population-based Epidemmentioning

confidence: 99%

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth

2020

View full text Add to dashboard Cite

Introduction: Recent years have seen a dramatic escalation of off-label prescribing for gabapentin and pregabalin (gabapentinoids) owing in part to generic versions of each being released over the past two decades, but also in part as a response to increasing calls for multimodal and non-opioid pain management strategies. In this context, several recent articles have been published alleging widespread misuse, with speculations on the unappreciated addictive potential of the gabapentinoid class of Digital Features To view digital features for this article go to

show abstract

“…22 Additional caution should also be noted for rising concern of the abuse and misuse of gabapentinoids. A recent published analysis 23 of the FDA Adverse Events Reporting System revealed more than 600 cases of gabapentinoid abuse over a 4-year time period.…”

Section: Pregabalinmentioning

confidence: 99%

Management of treatment-resistant generalized anxiety disorder

Ansara¹

2020

Mental Health Clinician

View full text Add to dashboard Cite

Generalized anxiety disorder (GAD) is characterized by persistent and excessive worry. Around half of the patients treated for GAD will fail to respond to initial treatment. Treatment-resistant (or refractory) GAD is defined as failure to respond to at least 1 trial of antidepressant therapy at adequate dose and duration. Review of the literature indicates several potential medication classes and individual agents that can be used as augmentation strategies to treat residual symptoms when recommended therapy per clinical practice guidelines fails. A thorough literature search revealed 2 medication classes with the largest amount of data to support their use in treatment-resistant GAD treatment: gamma-aminobutyric acid–related agents and atypical antipsychotics. This article focuses on evidence-based recommendations for the use of these agents as adjunctive therapies for patients with treatment-resistant GAD. Different pharmacologic approaches to use these agents are demonstrated through 2 patient cases in which patients have failed first-line treatment options.

show abstract

Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS)

Cited by 80 publications

References 27 publications

Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions

Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth

Management of treatment-resistant generalized anxiety disorder

Contact Info

Product

Resources

About